GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Medicines Corp Ltd (SHSE:600511) » Definitions » EBIT

China National Medicines (SHSE:600511) EBIT : ¥2,931 Mil (TTM As of Sep. 2024)


View and export this data going back to 2002. Start your Free Trial

What is China National Medicines EBIT?

China National Medicines's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥657 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥2,931 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. China National Medicines's annualized ROC % for the quarter that ended in Sep. 2024 was 15.66%. China National Medicines's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 125.94%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. China National Medicines's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 15.46%.


China National Medicines EBIT Historical Data

The historical data trend for China National Medicines's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Medicines EBIT Chart

China National Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,475.02 1,974.15 2,488.52 2,714.76 2,962.46

China National Medicines Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 670.91 941.25 620.85 712.55 656.70

Competitive Comparison of China National Medicines's EBIT

For the Medical Distribution subindustry, China National Medicines's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China National Medicines's EV-to-EBIT Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, China National Medicines's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where China National Medicines's EV-to-EBIT falls into.



China National Medicines EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,931 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China National Medicines  (SHSE:600511) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

China National Medicines's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=2274.864 * ( 1 - 21.1% )/( (11020.275 + 11901.549)/ 2 )
=1794.867696/11460.912
=15.66 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=33553.84 - 13917.511 - ( 8616.054 - max(0, 14361.158 - 29184.077+8616.054))
=11020.275

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=34336.034 - 14136.383 - ( 8298.102 - max(0, 14617.484 - 29770.545+8298.102))
=11901.549

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

China National Medicines's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2626.804/( ( (907.22 + max(921.716, 0)) + (897.638 + max(1444.92, 0)) )/ 2 )
=2626.804/( ( 1828.936 + 2342.558 )/ 2 )
=2626.804/2085.747
=125.94 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9838.193 + 4961.497 + 147.135) - (13917.511 + 0 + 107.598)
=921.716

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10144.334 + 5257.412 + 288.396) - (14136.383 + 0 + 108.839)
=1444.92

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

China National Medicines's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=2931.35/18962.734
=15.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China National Medicines EBIT Related Terms

Thank you for viewing the detailed overview of China National Medicines's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


China National Medicines Business Description

Traded in Other Exchanges
N/A
Address
No. 8, Xibinhe Road, Floor 6-9, West Tower, 7th Floor, Yongdingmen, Dongcheng District, Beijing, CHN, 100077
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The Company has one main reportable segment, the Commercial segment, which consists of the operating segment of pharmaceutical sales. Its other reportable segments consist of pharmaceutical production and logistics segments The company is also engaged in proprietary Chinese medicines, Chinese medicine decoction pieces, Chinese medicinal materials, chemical preparations, chemical raw materials, antibiotics and biochemical drugs.
Executives
Chen Zhang Qing Director

China National Medicines Headlines

No Headlines